A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy
Latest Information Update: 12 Jan 2023
At a glance
- Drugs Atezolizumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms IMpower210
- Sponsors Roche
- 09 Jan 2023 Status changed from active, no longer recruiting to completed.
- 16 May 2022 Planned End Date changed from 29 Apr 2022 to 31 Dec 2022.
- 19 Oct 2021 Planned End Date changed from 1 Dec 2021 to 29 Apr 2022.